ABOUT US

Located in the San Francisco Bay Area, Celltheon has been serving the Biotherapeutics industry with innovation and dedication since its founding in 2012. Celltheon was founded as a California Corporation by Amita Goel, a leader in Cell Line Development and Expression Technologies, to develop the next generation in Cell Engineering technologies. Celltheon has patents, granted and pending, for its CHOK-1 derived SUPERCELL™ cell line and its unique DNA and RNA vector elements that are applicable for recombinant biotherapeutics such as Mabs, Difficult to Express Proteins (DEP) as well as for CAR-T, Gene Therapy and Cell Therapy applications. The CELLTHEON SMART™ Platform has been used to date in 60+ biotherapeutics for oncology, neurobiology and RA programs. Celltheon has also forged strategic partnerships with industry leading companies to offer end-to-end cDNA to manufacturing solutions: scale-up process equipment, cell culture media and analytical screening tools for developing processes based on Quality-By-Design (QBD). Using its technology foundation, Celltheon is now building the Nextgen cell engineering technologies for human autogeneic and autologous cells for in-vitro, ex-vivo and in-vivo therapeutic applications – which have a combined potential to grow to >$250B.

The Celltheon Team is comprised of seasoned industry veterans with deep experience in Cell Engineering, Vector Design, Molecular Biology, Antibody Engineering, CMC and Large-scale Manufacturing, Process Development, Purification, Analytics, QC/QA and Plant Design.